Low operating rates for the consumer genetic analysis service
First written in FY2016. 3 of 4 entries say "Mitigated", first in FY2019-Q1. Latest entry: FY2019-Q3.
0 other companies' latest entry also says "Mitigated".
- FY2019-Q3MitigatedAnnual report
「In the diagnostic analysis business, an increase in the number of pathology specimens and growth in contracted genetic analysis services, particularly DTC services, resulted in higher revenue year on year, up 8.5%.」
For the direct-to-consumer genetic analysis business, which was previously reported to have low utilization, growth in contracted genetic analysis services, particularly DTC services, and higher revenue have continued, indicating that the impact is easing. - FY2019-Q2MitigatedAnnual report
「An increase in the number of pathology specimens and growth in contracted genetic analysis services, particularly DTC services, resulted in higher revenue year on year, up 3.6%.」
For the direct-to-consumer genetic analysis business, which was previously reported to have low utilization, growth in contracted genetic analysis services, particularly DTC services, and higher revenue have continued, indicating that the impact of the low-utilization risk is easing. - FY2019-Q1MitigatedAnnual report
「Performance for the cumulative first quarter of the current consolidated fiscal year benefited from an increase in the number of pathology specimens and growth in contracted genetic analysis services, particularly DTC services, resulting in higher revenue year on year, up 6.1%.」
For the direct-to-consumer genetic analysis service, which was previously reported to have low utilization, growth in contracted genetic analysis services, particularly DTC services, and higher revenue in the diagnostic analysis business are cited, indicating that the impact of the low-utilization risk is easing. However, there is no statement that the past risk has been completely resolved. - FY2016First statedAnnual report
「The direct-to-consumer genetic analysis service launched in November the year before last operated at a level well below break-even. As a result, operating profit was limited to ¥13.136 million, down 59.7% year on year.」
The direct-to-consumer genetic analysis service has operated at a level well below break-even and is specifically cited as a factor behind the decline in profit in the advanced medical business.